clinical trial · NCT07258121
Study of ZGGS34 in Participants With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd·phase2·recruiting·n = 400
Solid TumorZG006
brief summary
This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and safety of ZGGS34 (± chemotherapy) in selected MUC17-positive advanced solid tumor participants.
started
Dec 31, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 28, 2026
official title
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZGGS34 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol